Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$20.92 USD
-0.27 (-1.27%)
Updated Jan 14, 2025 04:00 PM ET
After-Market: $20.84 -0.08 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CDTX 20.92 -0.27(-1.27%)
Will CDTX be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDTX
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Other News for CDTX
Cidara Therapeutics Announces Leadership Changes and Appointments
Twelve option delistings on December 23rd
Twelve option delistings on December 23rd
Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders
Cidara Therapeutics files to sell 7.04M shares of common stock for holders